Skip to content
  • Clinical Evidence
  • PAD
    • PAD
    • DETOUR System
    • DETOUR System Evidence
    • DETOUR System Resources
    • DETOUR System Reimbursement
  • AAA
    • AAA
    • ALTO
    • AFX2
    • EVAR for Women
    • EVAR Portfolio Resources
  • Procedural Training
  • For Patients
  • About Us
    • About Us
    • News
    • The Team
    • Careers
    • Contact Us
  • Clinical Evidence
  • PAD
    • PAD
    • DETOUR System
    • DETOUR System Evidence
    • DETOUR System Resources
    • DETOUR System Reimbursement
  • AAA
    • AAA
    • ALTO
    • AFX2
    • EVAR for Women
    • EVAR Portfolio Resources
  • Procedural Training
  • For Patients
  • About Us
    • About Us
    • News
    • The Team
    • Careers
    • Contact Us
Back to News
  • December 27, 2016

Endologix Announces Temporary Hold on AFX to Resolve a Manufacturing Issue

PrevPreviousEndologix Receives Australian Therapeutic Goods Administration (TGA) Approval for AFX®2 Bifurcated Endograft System
NextEndologix Resumes Shipments and Procedures with AFX® and Some Sizes of AFX®2 Schedules Conference Call for December 30, 2016 at 9:00 am ETNext
FIND IFU HERE
Youtube Linkedin Twitter

Compliance

Privacy Policy

Safety Information

Anti-Trafficking/Modern Slavery

Cookie Policy

Terms & Conditions

Patents

© 2025 Endologix LLC. All rights reserved.

Endologix® products and associated components are not available in all countries or regions. Please contact your Endologix representative for details regarding product availability. Prior to use, refer to the “Instructions for Use” for complete and specificindications, contraindications, all warnings and precautions. Rx only.